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Context: Ibandronate, a potent, nitrogen-containing bisphosphonate
developed for intermittent administration in postmenopausal osteo-
porosis, aims to overcome current adherence issues with daily and
weekly oral bisphosphonates through once-monthly oral dosing.
Objective: The purpose of this study was to investigate the safety,
pharmacodynamics, and pharmacokinetics of once-monthly oral
ibandronate.
Design: A randomized, 3-month, double-blind, placebo-controlled,
phase I study (Monthly Oral Pilot Study) was conducted.
Setting: The study was conducted at five clinical trial centers in the
United Kingdom and Belgium.
Patients or Other Participants: Subjects were postmenopausal
women (age, 55–80 yr; 3 yr post menopause; n  144).
Intervention(s): Once-monthly oral ibandronate 50, 100, or 150 mg
or placebo was used. After the first cycle, the 50-mg arm was split,
with participants continuing on either 50 or 100 mg.
Main Outcome Measure(s): Primary outcome measures were
safety, serum and urinary C-telopeptide (CTX), and serum ibandr-
onate AUC0-.
Results: Once-monthly oral ibandronate was well tolerated, with a
similar overall and upper gastrointestinal safety profile to placebo.
Once-monthly ibandronate was also highly effective in decreasing
bone turnover; substantial reductions from baseline in serum CTX
(56.7% and40.7% in the 150- and 100-mg arms, respectively; P
0.001 vs. placebo) and urinary CTX (54.1% and 34.6%, respec-
tively;P 0.001 vs. placebo) were observed at d 91 (30 d after the final
dose). Analysis of the area under the effect curve (d 1–91) for change
from baseline (percent  days) in serum CTX and urinary CTX in-
dicated a dose-response relationship. The AUC0- for ibandronate
increased with dose but not in a dose-proportional manner.
Conclusions: These findings indicate a potential role for once-
monthly oral ibandronate in the treatment of postmenopausal
osteoporosis. (J Clin Endocrinol Metab 90: 5018–5024, 2005)
OSTEOPOROSIS IS A chronic, yet often silent, systemicskeletal disease, characterized by low bone mass and
microarchitectural deterioration of bone tissue, leading to
increased bone fragility and susceptibility to fracture. It is a
serious condition that, as a result of its most debilitating
symptom, the fragility fracture, has an immense impact on
society (1). Conservative estimates suggest that more than
one third of adult women will sustain one or more osteo-
porosis-related fractures in their lifetime (1, 2), resulting in
substantial disability (3–5), mortality (6–9), and health care
expenditure (3, 10, 11).
Although effective therapies are available for its manage-
ment, osteoporosis, like other chronic, largely asymptomatic
diseases, is associated with poor therapeutic adherence. In-
deed, recent studies indicate that both compliance and per-
sistence with current osteoporosis medications are subopti-
mal (12–18). A negative impact on therapeutic outcomes has
also been observed, with nonadherent patients showing
smaller increases in bone mineral density (BMD) (16, 17),
smaller decreases in bone turnover (17, 19), and reduced
antifracture efficacy (15, 18) compared with adherent
counterparts.
Adherence to therapy can be enhanced by decreasing the
frequency and complexity of dosing (20). In osteoporosis
management, patient preference for less complex dosing is
illustrated by the recent introduction and rapid uptake of
weekly oral bisphosphonate regimens (21–24). Prescription
claims database studies [IHCIS (Integrated Healthcare In-
formation Services, Inc.) (12); NDCHealth (13)] highlight the
positive impact of less frequent bisphosphonate dosing on
therapeutic adherence, with improved 1-yr persistence rates
observed with the weekly vs. daily dosing schedule (54.5 vs.
36.9 and 44.2 vs. 31.7%, respectively). However, although
weekly administrations go some way to enhancing thera-
peutic adherence, these findings also indicate that persis-
tence rates remain suboptimal (12, 13).
Ibandronate is a potent, nitrogen-containing bisphospho-
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nate that aims to overcome current adherence issues with
oral bisphosphonates through the provision of less frequent
dosing regimens, such as once monthly. Unlike other
bisphosphonates, the high potency of ibandronate (25), to-
gether with its favorable tolerability profile, allow dosing
with extended intervals, beyond the weekly dosing concept.
A recent, randomized, double-blind, placebo-controlled,
phase III, fracture-prevention study [oral iBandronate Os-
teoporosis vertebral fracture study in North America and
Europe (BONE)] demonstrated the antifracture efficacy and
safety of daily (2.5 mg) and intermittent (20 mg every other
day for 12 doses, followed by more than 2 months drug-free
interval every 3 months) oral ibandronate regimens in post-
menopausal women with osteoporosis (26). After 3 yr, daily
and intermittent oral ibandronate significantly reduced the
risk of new vertebral fractures, by 62% (P 0.0001) and 50%
(P  0.0006), respectively, relative to placebo (difference
between treatments, P  0.2785). Significant and substantial
increases in BMD and decreases in biochemical markers of
bone turnover were also observed. Ibandronate was well
tolerated, with a similar safety profile to placebo.
In light of these findings and the beneficial effects for
adherence with less frequent bisphosphonate administra-
tions, we performed a randomized, double-blind, placebo-
controlled, phase I, dose-ranging study [Monthly Oral Pilot
Study (MOPS)] to establish the feasibility of once-monthly
dosingwith oral ibandronate in postmenopausalwomen, the
findings of which are reported herein.
Subjects and Methods
Participants
All participants were women, 55–80 yr old, who were postmeno-
pausal for at least 3 yr at enrollment. No specific lumbar spine BMD
inclusion criteria were set. Participants were excluded from the study if
they had: a dietary calcium intake less than 500 mg/d; received drugs
known to affect bone metabolism within 6 months, treatment with
bisphosphonates or fluoride within 12 months or for more than 2 yr, or
any investigational drug within 30 d; undergone bilateral oophorec-
tomy; or diseases or disorders known to influence bone metabolism,
including chronic gastrointestinal (GI) or liver disease, malignant dis-
ease within 10 yr, diagnosed breast cancer within 20 yr, alcoholism,
primary hyperparathyroidism, Paget’s disease, osteomalacia, or active
thyroid disease without treatment. Participants with esophageal abnor-
malities, active gastric or duodenal ulcers, renal impairment, vitamin D
deficiency, allergy to bisphosphonates, or serum calcium levels at least
2.6 or less than 2.0 mmol/liter were also excluded. Certain concomitant
medications and supplements were allowed but had to be recorded on
the case report form. All participants provided written informed con-
sent; the study complied with the requirements of the Declaration of
Helsinki andwith the International Conference onHarmonizationGood
Clinical Practice and was approved by the Ethics Committees at the
participating centers.
Study design
Conducted in five centers, of which four were in the United Kingdom
and one in Belgium, MOPS was a randomized, double-blind, placebo-
controlled, phase I, dose-ranging study of the safety, pharmacodynam-
ics (PDs), and pharmacokinetics (PKs) of monthly oral ibandronate in
postmenopausal women. At enrolment, participants were randomized
to receive three cycles of monthly oral (every 30 d) placebo or 50, 100,
or 150 mg ibandronate (Fig. 1). Because flu-like symptoms have been
observed in a minority of patients receiving nitrogen-containing
bisphosphonates, the 50-mg arm was split into two arms (n  18) after
the first dosing cycle to separate the effects of dose and first-time treat-
ment, with participants continuing on either 50 or 100 mg ibandronate
for the remaining cycles (Fig. 1).
Study medication was supplied in monthly blister packages contain-
ing three film-coated tablets (50 mg ibandronate or placebo) to the
desired dose. All tablets were taken with 240 ml (8 oz) plain water after
an overnight fast of at least 6 h. Participants were instructed to maintain
an upright posture and continue fasting for at least 60 min after dosing.
A standardized breakfast was taken 1 h after drug administration.
Dose selection
The ibandronate regimens evaluated in MOPS were selected on the
basis of prior clinical experience (26) and clinical trial simulation (27). In
BONE, daily and intermittent oral ibandronate regimens of the same
cumulative dose (225–240mg every 3months) provided comparable (no
significant difference) reductions in the risk of new vertebral fractures
and changes in BMD and biochemical markers of bone turnover. How-
ever, similar to studies of oral daily andweekly bisphosphonates (21, 22),
andmost likely a result of the extension of the dosing interval, a nominal,
yet consistent, advantage was observed in favor of the daily regimen.
Thus, in MOPS, it was considered reasonable to explore the efficacy and
safety of oral doses beyond the cumulative monthly dose provided by
the daily regimen (i.e. 75 mg). Simulated biomarker responses for a
range of monthly oral ibandronate regimens supported this conclusion
(27).
Randomization
A centralized randomization procedure was used to assign partici-
pants to the respective treatment arms. However, given the limited
experience with the investigational regimens in the study population, a
three-step randomization procedurewas used to gradually expose small
numbers of participants to increasing doses of oral ibandronate. In this
way, additional participants were only exposed to higher doses of oral
ibandronate after the safety of the lower doses had been established. To
this end, a data safety review committee (DSRC) was established from
statisticians and clinicians who were not involved in the study. The
DSRCwas not blinded to treatment, and they monitored adverse events
during each step. After each step, the DSRC authorized the exposure of
more participants to higher doses of oral ibandronate. In the first step,
participants were allocated only to placebo or 50 or 100 mg ibandronate.
In the second step, nine participants were allocated to 150 mg ibandr-
onate. In a third step, a further 27 participants were allocated to 150 mg
ibandronate.
Study endpoints
Safety parameters were: adverse events (including abnormal labo-
ratory findings), and episodes of flu-like symptoms (e.g. fatigue, fever,
chills, myalgia, and arthralgia). Serum laboratory safety parameters
(hematology, biochemistry) were measured at screening and on d 1, 2,
5, 31, 35, 61, 62, 65, and 91. PTH vs. albumin/calcium was measured at
FIG. 1. Study design and patient disposition in MOPS.
Reginster et al. • Monthly Ibandronate in Postmenopausal Women J Clin Endocrinol Metab, September 2005, 90(9):5018–5024 5019
 at Bibliotheque de la Faculte de Med - Univ De Liege on July 13, 2009 jcem.endojournals.orgDownloaded from 
d 1 and 91. 25-Hydroxycholecalciferol wasmeasured at screening. Urine
safety laboratory parameters were measured at screening and at d 1, 2,
61, 62, and 91.Using a supplied thermometer, participants recorded their
body temperature on d 1–5, 31–35, and 61–65.
The primary PD endpointwas relative change (percent) frombaseline
in concentrations of the C-telopeptide (CTX) of the -chain of type 1
collagen, a sensitive biochemical marker of bone resorption, in serum
(sCTX) and urine (uCTX) at d 91. An exploratory analysis of the area
under the effect curve (AUEC; d 1–91) for relative change (percent 
days) in sCTX and uCTXwas also performed. sCTX concentrationswere
measured in blood samples taken between 0800 and 1000 h, after an
overnight fast. uCTX concentrations were assessed in the second morn-
ing spot urine. Blood and urine samples were taken on d 1 (baseline),
9, 17, 23, 31, 61, 69, 77, 83, and 91. In addition, sCTX was measured on
d 5 and 65. Concentrations of sCTX and uCTX (creatinine-corrected)
were quantified (centrally) using an automated analyzer (ELECSYS
2010; Roche Diagnostics, Basel, Switzerland) and an ELISA (CrossLaps
EIA kit; Roche Diagnostics), respectively.
The primary PK parameter for the estimation of systemic exposure
was the area under the concentration time curve (AUC0-) for ibandr-
onate in serum after the first dose in each group. Secondary PK param-
eters were: maximum observed plasma concentration (Cmax); amount of
drug excreted in urine (Ae); renal clearance (CLR), calculated as Ae0–48
h divided by AUC0–48 h; and plasma elimination half-life (t1/2), calcu-
lated as ln (2)/kel where kel is the apparent elimination rate determined
by linear regression analysis of terminal data points. Blood samples for
PK analysis were taken at 0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and
192 h post dose after the first cycle only and urine samples at 0–6, 6–12,
12–24, 24–48, 48–72, and 72–96 hpost dose after the first and third cycles.
Concentrations of ibandronate in serum and urine were determined by
ELISA and gas chromatography/mass spectrometry, respectively, at a
centralized laboratory (MDS Pharma Services, Zurich, Switzerland AG).
PK parameters were estimated frommodel-independentmethods (Win-
nonlin Professional version 3.1 and version 4.0, Pharsight, Mountain
View, CA; Excel 97 SR-2, Microsoft, Redmond, WA) using established
equations.
Statistical analyses
Safety. All patients who received at least one dose of study medication,
whether withdrawn prematurely or not, were included in the safety
analysis. The frequency, incidence, intensity, and causal relationship of
all adverse events were tabulated. Laboratory safety variables were
considered evaluable in those patients who received treatment and for
whom safety values for the first visit and at least one follow-up visit
during the treatment period were available.
PDs.The primary analysis of PD variableswas based on the per-protocol
(PP) population. Patients were included in the PP analysis if none of the
inclusion criteria were violated, none of the exclusion criteria held true
for which an effect on the variable might be assumed, they were com-
pliant to therapy, and at least one bone resorption parameter was de-
termined at baseline and at least one thereafter. To support the findings
from the PP analysis, PD variables were also analyzed on an intent-to-
treat (ITT) basis. Patients were included in the ITT analysis if they were
randomized to therapy and bonemarkerswere followed up at least once
after baseline. For the ITT population only, if the d-91 result wasmissing
for any bone resorption marker, the last nonmissing postbaseline ob-
servation was used for the d-91 analysis. An extended Wilcoxon rank-
sum test was used to establish differences in median relative change
(percent) and AUEC (percent  days; d 1–91) for sCTX and uCTX
between the treatment arms.
PKs. A one-way ANOVA with factor dose was applied to dose-normal-
ized and log-transformed values of AUC0-, the primary PK variable.
Based on the results of thisANOVA, the systemic exposure at the 100-mg
and 150-mg doses was expressed as a ratio to the value obtained at the
50-mg dose. By estimating mean ratios together with 95% confidence
intervals (CI) for the two higher doses, and because AUC0- values were
normalized for dose, dose-proportionality of systemic exposure could be
evaluated. An identical analysis was performed for the secondary PK
variable Cmax. An exploratory ANOVA with the factors treatment, sub-
ject nested in treatment and period was applied to dose-normalized and
log-transformed values of Ae (cycles 1 and 3) to estimate intrasubject
variability.
Results
Disposition and baseline characteristics
Of the 218 participants screened, 144 were randomized to
treatment and received at least one dose of studymedication,
forming the ITT/safety population (Fig. 1). Of these partic-
ipants, 130met the criteria for inclusion in the PP population.
Overall, four participants withdrew from the study: three
due to adverse events (two in the placebo group and one in
the 150-mg ibandronate group), and one (placebo group)
because continuous clotting prevented blood samples from
being taken.
The baseline characteristics of the ITT/safety population
are summarized in Table 1. Treatment arms were well bal-
anced in terms of age, weight, and height. However, in the
absence of specific BMD inclusion criteria, some participants
were clearly osteoporotic (T-score2.5), others osteopenic
(T-score  1 to 2.5), and others normal (T-score  1),
with respect to BMD at the lumbar spine.
Safety
Overall safety. At the studied doses, once-monthly oral iban-
dronate was well tolerated, with a safety profile similar to
placebo (Table 2). Overall, no apparent relationship between
adverse events and dose was observed. No differences were
observed among study arms in the overall incidence of ad-
verse events, drug-related adverse events, and overall or
drug-related adverse events resulting in withdrawal (Table
2). Adverse events weremostlymild tomoderate in intensity
and typical of the bisphosphonate class. No serious adverse
events or deaths were reported (Table 2). No clinically rel-
evant changes in laboratory safety parameterswere observed
in the active treatment arms relative to placebo. In particular,
there were no changes in hepatic or renal function, serum
calcium, or PTH. The number of patients experiencing flu-
like symptoms was similar across the placebo and active
treatment groups and did not increase with increasing iban-
dronate dose [20, 8, 6, 17, and 16 patients in the placebo; 50,
50/100, 100, and 150mg ibandronate treatment arms (n 36,
18, 18, 36, and 36), respectively]. The majority of participants
TABLE 1. Mean (range) baseline patient characteristics (ITT/safety population)
Placebo (n  36) 50 mg (n  18) 50/100 mg (n  18) 100 mg (n  36) 150 mg (n  36)
Age (yr) 63.9 (55–79) 65.7 (61–74) 61.7 (55–77) 64.1 (56–77) 63.3 (55–79)
Weight (kg) 68.9 (54–105) 67.6 (54–86) 73.9 (54–108) 69.2 (52–101) 69.0 (54–100)
Height (cm) 161.0 (151–174) 161.3 (148–179) 161.2 (148–175) 162.0 (151–176) 161.3 (152–174)
Lumbar spine
BMD T-score
1.2 (3.4 to 2.2) 1.9 (2.9 to 1.0) 0.3 (2.3 to 1.1) 1.1 (3.7 to 1.8) 0.8 (3.0 to 2.1)
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reporting flu-like symptoms experienced a single event in
isolation.
Upper GI tolerability. The total number of upper GI adverse
events occurringwithin 3 d of treatment, and thusmost likely
to be a reflection of treatment effect, was comparable across
the treatment arms (6, 0, 4, 8, and 9 events in the placebo; 50,
50/100, 100, and 150-mg arms, respectively). Regarding up-
perGI adverse events occurring at any time during the study,
and not just within 3 d of therapy, a slightly higher number
of events occurred in the 100- and 150-mg arms (15 events per
arm) relative to the other arms (12, 3, and 11 events in the
placebo; 50- and 50/100-mg arms, respectively). Themajority
of these adverse events were mild in intensity.
PDs
Baseline concentrations of sCTX and uCTX did not differ
appreciably among groups. The median concentrations in
the five groups ranged from 0.42–0.47 ng/ml for sCTX and
from 175.7–212.3 g/mmol for uCTX. The smallest and larg-
est values (all groups) were 0.06 and 1.33 ng/ml, respec-
tively, for sCTX and 22.4 and 546.8 g/mmol for uCTX.
At the studied doses, once-monthly oral ibandronate was
effective in reducing bone turnover, as demonstrated by
substantial decreases from baseline in median sCTX and
uCTX concentrations at d 91 in the active treatment arms
(primary PD endpoint; Table 3); decreases vs. baseline were
statistically significant for all dose groups (overall P 0.0001
byKruskal-Wallis test). Themedian reductions frombaseline
in sCTX and uCTX concentrations were 56.7 and 54.1%, re-
spectively (150-mg arm) and 40.7 and 34.6% (100-mg arm),
compared with 12.3 and 5.5% in the placebo arm (PP anal-
ysis). The differences between active treatment and placebo
in the median reductions from baseline were significant for
all but the 50-mg group (P  0.001 by extended Wilcoxon
rank-sum test; Table 3). The results of the ITT analysis were
similar to those of the PP analysis. Analysis of the AUEC (d
1–91) for relative change (percent days) in sCTX and uCTX
indicated a dose-response relationship (Fig. 2).
PKs
A summary of the PK parameters after the first oral ad-
ministration of 50, 100, or 150 mg ibandronate is presented
in Table 4.
Ibandronate in serum. The mean serum AUC0- associated
with the first dose of each of the monthly dosing schedules
(primary PK endpoint) is shown in Fig. 3. As expected, sys-
temic exposure in participants receiving 50 mg ibandronate
(50- and 50/100-mg arms) was broadly similar. At higher
doses (100 mg and 150 mg), however, systemic exposure
(AUC0-) appeared to increase disproportionately to dose
(Fig. 3). Subsequent statistical analysis (ANOVA) of the
AUC0- gave mean systemic exposure ratios (relative to the
50-mg dose) of 130% (95% CI, 94–180%) and 191% (95% CI,
138–265%) for the 100-mg and 150-mg ibandronate groups,
respectively. Given that theCI for the 150-mg-dose groupdid
not contain the equivalence value (100%), the null hypothesis
of dose proportionality for the AUC0- between all three
groups was rejected (P  0.0006), and it was concluded that
the AUC0-was not dose-proportional among the three dose
groups. ANOVA of the secondary PK parameters, serum
Cmax and Ae, confirmed this finding. A trend toward an
increase in t1/2 with increasing dose (Table 4) was considered
to be a result of low terminal serum concentrations, which
approached the limits of assay quantification.
Ibandronate in urine. The overall recovery of ibandronate (Ae)
in urine was 0.2–0.4%, with the majority being recovered
within the first 6 h post dose (Fig. 4). No differences were
observed in Ae for the first and third dosing cycles for each
dosing arm. During the first dosing cycle, Ae was slightly
higher in the 150-mg arm (0.38%) compared with 100- and
50-mg arms (0.26–0.29%). However, in the third dosing cy-











Any adverse event 34 (94) 18 (100) 17 (94) 33 (92) 32 (89)
Any drug-related adverse eventa 3 (8) 3 (17) 0 2 (6) 2 (6)
Any serious adverse event 0 0 0 0 0
Any adverse event leading to withdrawal 2 (6) 0 0 0 1 (3)
Any drug-related adverse event leading to withdrawala 0 0 0 0 0
Any adverse event leading to death 0 0 0 0 0
a Adverse event considered “probably” related to treatment.
TABLE 3. Median change (%) from baseline in serum and urine concentrations of CTX at d 91 after monthly treatment with oral
ibandronate (PP population)
Placebo 50 mg 50/100 mg 100 mg 150 mg
sCTX
vs. baseline 12.3 (27.7, 3.3) 22.3 (39.6, 9.1) 49.6 (61.4, 35.4) 40.7 (54.0, 25.9) 56.7 (70.2, 39.7)
vs. placebo 9.0 (22.2, 5.9) 32.8a (45.6, 16.5) 23.7a (35.2, 10.4) 38.6a (50.0, 26.1)
uCTX
vs. baseline 5.5 (25.9, 14.2) 13.4 (40.9, 21.3) 54.8 (64.2, 32.7) 34.6 (58.6, 18.1) 54.1 (76.4, 42.6)
vs. placebo 5.3 (26.9, 20.6) 40.5a (58.8, 20.9) 32.0a (48.9, 14.3) 51.7a (65.6, 36.4)
Interquartile limits are given in parentheses. Rows for placebo show differences between medians (95% CI) in the active and placebo groups.
a P  0.001 for ibandronate vs. placebo, extended Wilcoxon rank-sum test.
Reginster et al. • Monthly Ibandronate in Postmenopausal Women J Clin Endocrinol Metab, September 2005, 90(9):5018–5024 5021
 at Bibliotheque de la Faculte de Med - Univ De Liege on July 13, 2009 jcem.endojournals.orgDownloaded from 
cle, Ae was similar among the 150-, 100-, and 50/100-mg
arms (0.34, 0.31, and 0.33%, respectively) butwas higher than
in the 50-mg arm (0.18%). An apparent trend toward a de-
crease in the CLR of ibandronate with increasing dose was
observed. However, this was considered to be the result of
the incomplete definition of the AUC of ibandronate in
plasma at lower doses.
Discussion
Ibandronate is a potent, nitrogen-containing bisphospho-
nate with proven antifracture efficacy when administered as
a daily (vertebral fracture risk reduction, 62%) or intermittent
oral regimen (vertebral fracture risk reduction, 50%) with a
between-dose interval of more than 2months towomenwith
postmenopausal osteoporosis (26). Ibandronate has also
been shown to provide substantial and comparable increases
in BMD at the lumbar spine and hip and decreases in bio-
chemical markers of turnover when administered continu-
ously or less frequently (26, 28). A safety profile similar to
that of placebo has also been demonstrated in numerous
studies of oral ibandronate, independent of the administra-
tion schedule and population characteristics (26, 29–33).
In the current study, we explored the feasibility of admin-
istering ibandronate as a once-monthly oral regimen in post-
menopausal women. Specifically, we explored the tolerabil-
ity, PD, and PK of three cycles of monthly oral 50, 50/100,
100, or 150 mg ibandronate, relative to placebo. At the stud-
ied doses, once-monthly oral ibandronatewaswell tolerated,
with a safety profile similar to that of placebo. Adverse
events were typical of the bisphosphonate class, with no
unexpected safety concerns reported. The number of upper
GI safety adverse events within 3 d of dosing was compa-
rable across treatment arms. These findings are consistent
with prior studies of oral ibandronate in women with and
without postmenopausal osteoporosis, in which oral iban-
dronate was shown to be extremely well tolerated and to
have a safety profile similar to that of placebo when admin-
istered continuously (2.5 mg), weekly (20 mg), or intermit-
tently (20 mg every other dose for 12 doses every 3 months)
(26, 29–33). A favorable tolerability profile has been observed
also in patients with metastatic bone disease receiving high
individual and cumulative daily doses of ibandronate: in
clinical trials, oral daily ibandronate (50 mg) administered
for 96 wk was well tolerated, with a safety profile similar to
that of placebo (34).
In addition to its good tolerability, once-monthly oral iban-
dronate was effective in suppressing bone resorption. At d
91, 30 d after the final administration of study medication,
substantial and significant relative reductions in median
sCTX and uCTX levels were observed. Analysis of the AUEC
(d 1–91) for the median relative change in sCTX and uCTX,
an integrated PD assessment reflecting the total level of sup-
pression over the analysis period rather than at a single time
point, indicated a dose-response relationship for monthly
oral ibandronate. Thus, whereas acknowledging the limita-
tions of the MOPS study, these findings, especially those in
the higher dose-containing arms (100 and 150 mg), highlight
a strong potential for clinically meaningful efficacy with
monthly oral ibandronate.
Systemic exposure to ibandronate increased with dose but
not in a dose-proportional manner, as shown by calculations
of the ratio of dose-normalized AUC values at the higher
ibandronate doses relative to the 50-mg value (130% for the
100-mg group and 191% for the 150-mg group). Conse-
quently, a linear association between dose and serum expo-
FIG. 2. Median values of AUEC, calculated as percentage change
between baseline and d 91 in concentrations of sCTX and uCTX after
monthly treatment with oral ibandronate (PP population).
FIG. 3. Mean AUC0- for monthly oral ibandronate in serum (initial
dose only).
TABLE 4. Summary of PK parameters after the first oral administration of monthly oral ibandronate [mean (SD)]
Ibandronate dose AUC0– (ng/hml) Cmax (ng/ml) t1/2 (h) CLR (ml/min)
50 mg (n  18) 37.5 (59.2)a 10.7 (21.9) 26.9 (23.2) 76.8 (35.0)
50/100 mg (n  18) 38.1 (21.6) 11.7 (7.74) 33.4 (21.9) 69.5 (19.8)
100 mg (n  36) 84.1 (53.6) 22.8 (18.9) 58.6 (22.5) 59.4 (18.4)b
150 mg (n  36) 208 (185) 49.7 (44.0) 72.0 (15.8) 56.9 (16.6)c
a n  16.
b n  35.
c n  33.
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sure to ibandronate was not demonstrated at the studied
doses. However, consistent with the dose-independent bio-
availability reported for alendronate (at doses of up to 80mg)
(35) and dose-proportional PKs of risedronate (at doses up
to 30 mg) (36), serum exposure with ibandronate is linear up
to a 50-mg dose (37). The reason for disproportionate expo-
sure with oral ibandronate at doses greater than 50 mg is
unknown. Increased absorption efficiency at high ibandr-
onate doses cannot be completely ruled out based on these
data. The AUC0- for the 50- and 100-mg ibandronate doses
was consistent with prior phase I PK studies of oral iban-
dronate (37).
As previously stated, recent studies have shown that ther-
apeutic adherence with osteoporosis medications, including
daily and weekly oral bisphosphonates, is suboptimal (12–
18). Commonly cited reasons for nonadherence include dos-
ing convenience and/or complexity (38, 39) and side effects
(38–40). A convenient once-monthly tablet with a favorable
safety and tolerability profile may therefore provide adher-
ence benefits in postmenopausal osteoporosis.
The findings of the MOPS study demonstrate that once-
monthly oral ibandronate is well tolerated and efficacious in
postmenopausal women. However, given the small number
of participants and absence of standardized calcium and
vitamin D supplementation in theMOPS study, further eval-
uation of the once-monthly ibandronate dosing concept is
warranted. A large-scale, randomized, double-blind, phase
III study [Monthly Oral Ibandronate in Ladies (MOBILE)]
will establish the efficacy and safety of 2 yr of treatment with
the 100- and 150-mg monthly oral ibandronate regimens in
postmenopausal women with osteoporosis. Similar to the
studies of oral weekly and daily alendronate (21) and risedr-
onate (22), MOBILE is a noninferiority study, which uses the
proven oral daily ibandronate regimen as an active compar-
ator. Vertebral fracture efficacywill be derived if themonthly
oral regimens show noninferiority to the oral daily regimen
for lumbar spine BMD change (percent) at 1 yr. Positive
outcomes from this study will likely provide physicians and
patients with an additional dosing option for the manage-
ment of postmenopausal osteoporosis.
Conclusions
The findings of the MOPS study demonstrate that once-
monthly oral ibandronate dosing is well tolerated and effi-
cacious in suppressing bone turnover in postmenopausal
women. However, given the limitations of the MOPS study,
additional evaluation of once-monthly ibandronate dosing is
warranted. TheMOBILE study is evaluating the efficacy and
safety of 100- and 150-mg once-monthly oral ibandronate
regimens in postmenopausal women with osteoporosis.
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